Slovenia R&D and Manufacturing Site

Global Presence

Slovenia R&D and Manufacturing Site

It is the first CDMO-type company in the pharmaceutical industry in Slovenia, dedicated to providing comprehensive services to customers, encompassing synthesis route development, process familiarization, analytical method development and validation, and process scale-up.

More about of Slovenia, EU

Kolodvorska cesta 27, 1234 Mengeš

2023Founded

R&D and kilo-labs have been put into operation, and construction of the pilot plant has also started. The facility is equipped with advanced process development and analysis equipment, as well as a complete project operation team.

25000m²Total Factory

An integrated and production-oriented R&D team, driven by the right-first-time philosophy at scale, features process scale-up experts, chemical engineers, and analytical chemists.

R&D Capabilities

Pressure Reactions (hydrogenation, Carbonylation, etc.)
Cryogenic - High Temperature Reactions (-80 to 200 °C)
Enzymatic Reactions and Biocatalysis
Organometallic Chemistry (Grignard, RLi, etc.)
Protective Groups Handling
Homogeneous and Heterogeneous Catalysis
Precious Metals Catalysis (cross-couplings, etc.)
Special/Hazardous Reagents (borane, cyanides, dimethyl sulfate, chlorine, bromine, triphosgene, etc.)
Stereoselective Synthesis and Chiral Resolution

Services

Small Molecule

Porton offers efficient, flexible, and high-quality solutions for custom development and production of small molecule APIs, as well as technical services throughout the entire lifecycle from pre-clinical to commercial stages to our worldwide partners.

One Porton One Quality

Compliance standards, Continuous improvement, Customer oriented

Quality management runs throughout the entire process of the drug life cycle. The quality management system of the drug product site is built in accordance with international standards and continues to adhere to the quality concept of 'more well-established system, more controllable quality.' This ensures that the GMP activities of the drug product site meet the requirements of international quality management systems and market drug regulatory agencies, including those of China, the European Union, FDA, and other mainstream regulations.

Case Studies

Continuous Improvement of Project Life Cycle Management, Benefiting Customers by Reducing Total Cost

Molecular Modeling and Data Science for De-risking and Cost- saving of Pharmaceutical Development

Agile and Fast：Enabling Rapid Market Launch of Innovative Drugs from Preclinical to Commercialization in 18 Months

News

News2024-12-19

Porton Newsletter | Q4 2024 Recap

News2024-11-13

Porton Has Been Invited to the China–Slovenia Business and Investment Forum

News2024-10-14

Driving innovation and excellence in the CDMO industry, Porton at 2024 CPHI Europe

News2024-10-01

Porton Newsletter | Q3 2024 Recap

News2024-09-19

Porton Showcases At CPhI Europe, Meeting Your CDMO Experts In Booth 5C17

News2024-08-27

Connect with Porton at CPhI Europe 2024 @ Booth 5C17

News2024-06-29

Porton Experts Invited to Participate in the University of Perugia Master PRO-API Program, Aiding in the Training of Green Process Chemistry Professionals

News2024-05-23

Porton Pharma Solutions embark on the next frontier in Mengeš, Slovenia

News2023-06-23

Porton Pharma Solutions Expands Global Reach with New Site in Slovenia and Enhanced Manufacturing Capabilities

Slovenia R&D and Manufacturing Site

Small Molecules CDMO Services

Tides CDMO Services

Biologics and Conjugates CDMO Services

Advanced Therapy Medicinal
Products CRO & CDMO Services

Crystallization

Bio Catalysis

Metal Catalysis

Flow Chemistry

Prep-Chromatography

Milling

Chemical Engineering and Technologies

ESG Concept

ESG Policies

ESG Reports

Case Studies & Whitepapers

Events

News

Marketing Collateral

About Us

Global Presence

Corporate Governance

Investors

Digital Transformation

Career